Close Menu
Home » ArcherDx to Develop CDx for Celgene's Lymphoma Drug Candidate

ArcherDx to Develop CDx for Celgene's Lymphoma Drug Candidate

Nov 06, 2017
|
staff reporter

NEW YORK (Genomeweb) – ArcherDx announced on Monday an agreement to develop and commercialize a next generation sequencing-based companion diagnostic for Celgene's investigational drug CC-122 for diffuse large B cell lymphoma.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Commission's First Meeting

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

More Scrutiny

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Web of Neutrophil DNA

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

Science Explores Method to Infer Genotype-by-Environment Interactions

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

What's Popular?

In Companion Diagnostics

  1. Foundation Medicine to Seek FDA Approval for FoundationOne as CDx to Genentech's Rozlytrek

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.